INSIGHTS INTO ADHD CARE IN GERMANY BASED ON SHI CLAIMS DATA 03. March Results of the CoCA Study (Horizon 2020)

Similar documents
Too little, too late Real World Insights on Current Practice of Home Parenteral Nutrition in Germany

Contributions to health outcomes research Rheumatoid Arthritis. Study objective: Database: Author: Version: Date:

RD-ACTION DISSEMINATION PLAN TABLE I - STAKEHOLDER ANALYSIS

Bringing Together Clinical, Economic and Patient Reported Outcomes Data Future Of Real World Evidence. March IIeX Health, Philadelphia, PA

Boehringer Ingelheim Pharmaceuticals, Inc. & Univision. Making Diabetic Hispanics Healthier

Imaging Performance Partnership. A Data Driven Approach to Your Imaging Program Strategy

Older adults with alcohol use disorder in the German addiction care system: Characterization and specific needs

Funding of patient-oriented clinical research by the German Federal Ministry of Education and Research (BMBF)

Precision Health Economics, Not Just Genetics

Diagnoses and Health Care Utilization of Children Who Are in Foster Care and Covered by Medicaid

Economic Evaluation. Defining the Scope of a Costeffectiveness

WORK PACKAGE 4: LIFETIME COST OF CHILDHOOD OBESITY

Improving Type 2 Diabetes Therapy Compliance and Persistence in Brazil

Connecticut Medicaid Emerging Adults

Translating Health Services Research in Sickle Cell Disease to Policy

Annex 1: MINDMAP research teams

Background. Correlation between epilepsy and attention deficit hyperactivity disorder. Background. Epidemiology of ADHD among children with epilepsy

Jacqueline C. Barrientos, Nicole Meyer, Xue Song, Kanti R. Rai ASH Annual Meeting Abstracts 2015:3301

European map of investments in innovative digital solutions for AHA Early results

Medicare Severity-adjusted Diagnosis Related Groups (MS-DRGs) Coding Adjustment

Risk Classification Modeling to Combat Opioid Abuse

Guideline scope Persistent pain: assessment and management

Commercial Health Insurance Claims Data. for Studying HIV/AIDS Care. Senior Scientist, Innovus Epidemiology. David D.

Consolidated Comprehensive Research Plan: Pharmacologic Treatment of Attention Deficit Hyperactivity Disorder in Adults

Informatics and Data Analytics; How to make data meaningful? AHIMA World Congress Middle East Healthcare Information Summit October 2017

Invitation to Tender

Autism Spectrum Conditions

Jukti Kumar Kalita, PhD Business Analytics and Insights Pfizer Presented at:

DEMENTIA: IMPLEMENTATION REPORT AND CURRENT DEVELOPMENTS EU HEALTH

The treatment costs of ADHD A framework for future economic evaluations

CHRONIC LOW BACK PAIN

Economic evaluation of specific immunotherapy versus symptomatic treatment of allergic rhinitis in Germany Schadlich P K, Brecht J G

20% A Holistic Approach Built on Evidence OF U.S. ADULTS EXPERIENCE MENTAL ILLNESS EACH YEAR

Botswana Private Sector Health Assessment Scope of Work

We see health care. differently. Comprehensive data Novel insights Transformative actions Lasting value

Report to the Social Services Appropriations Subcommittee

PHARMO Database Network

Executive Board of the United Nations Development Programme, the United Nations Population Fund and the United Nations Office for Project Services

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE. Personality Disorder: the clinical management of borderline personality disorder

PROGRAMME INITIATION DOCUMENT MENTAL HEALTH PROGRAMME

Moving towards 2020 priorities for Public Health for the years Health and Consumers

Obesity Policy in the EU - evaluating the options. Cross-national findings

EU Funding for Global Health Research and Development (GH R&D) Cecile Vernant, Head of EU Advocacy, DSW EU 13 June 2014

Update from IMI PREFER: Patient preferences in benefitrisk assessments during the medical product lifecycle

Timely Referral to Outpatient Nephrology Care Slows Progression and Reduces Treatment Costs of Chronic Kidney Diseases

Powering mhealth. IM Associates. October 2016

Establishing LCA in the Healthcare Sector

Novartis: tackling adherence. ESPACOMP, September, 2010

About The Report. imarc. Key Questions Answered in this Report:

Corporate Social Responsibility Policy

The HIV Prevention England programme: what s next? Cary James May 2016

Pharmaceutical Pricing & Reimbursement Information. PPRI Project Co-ordination Sabine Vogler, Gesundheit Österreich GmbH

Early benefit assessment of new drugs 5-year experiences of AMNOG (from IQWiG s point of view)

Opinion 3 October 2012

The DIABETES CHALLENGE IN PAKISTAN FIFTH NATIONAL ACTION PLAN

TENNCARE Bundled Payment Initiative: Description of Bundle Risk Adjustment for Wave 4 Episodes

WHO HHS Workshop on Business Modeling for Sustainable Influenza Vaccine Manufacturing

The Diabetes Community Sentinel Project

3.1 Publishable summary

Tobacco Health Cost in Egypt

Lowering epilepsy-related treatment costs in the era of patient choice and value-based care

Using Predictive Analytics to Save Lives

Working for an International Organization in Public-Private Partnership : The Global Fund to Fight AIDS, Tuberculosis and Malaria

Fifth Annual National ACO Summit

Attention Deficit Hyperactivity Disorder

Defining High Users in Acute Care: An Examination of Different Approaches. Better data. Better decisions. Healthier Canadians.

Improving Type-2 Diabetes Therapy Adherence and Persistence in Turkey

Championing patients every step of the way

REFERENCE CODE GDHCER046 PUBLICAT ION DATE OCTOBER 2013 DIABETIC FOOT ULCERS - EPIDEMIOLOGY FORECAST TO 2022

FAMILY & CHILDREN S SERVICES STRATEGIC PLAN

Challenges for U.S. Attorneys Offices (USAO) in Opioid Cases

Big Data & Predictive Analytics Case Studies: Applying data science to human data Big-Data.AI Summit

Cost-effectiveness of evolocumab (Repatha ) for hypercholesterolemia

Provider Service Model. Collaborating for Success Jodi Stockslager, Sr. Provider Advocate, Provider Relations

Memorias Convención Internacional de Salud Pública. Cuba Salud La Habana 3-7 de diciembre de 2012 ISBN

67 Years of Leadership in Pharmacy. A Journey of Continuous Improvement

Executive Board of the United Nations Development Programme and of the United Nations Population Fund

Welcome Note by Dr. Helge Braun, Parliamentary State Secretary

DISEASE MANAGEMENT: A CASE FOR COST EFFECTIVENESS AND QUALITY. Presented by Rob Parke Lalit Baveja

Women Entrepreneurs in Austria 2017

Patterns and Cost of Health Care Transitions to Adult Care among Youth with Chronic Conditions in Ontario: A Population Based Cohort Study

Dry Eye Syndrome - Current and Future Players. GDHC1016FPR / Published May 2013

UnitedHealth Premium Program Case-mix, Severity and Risk

Cancer prevention and control in the context of an integrated approach

Dr. Nick Guldemond

Hana Ross, PhD American Cancer Society and the International Tobacco Evidence Network (ITEN)

REAL WORLD DATA GENERATION FOR MARKET ACCESS PURPOSES. Marcin Balcerzak Research Team Lead Farenta Oy

Transforming health through IT

ASBMR. Institute of Musculoskeletal Health and Arthritis (IMHA) Dr. Hani El-Gabalawy Scientific Director Canadian Institutes of Health Research

EPIDEMIOLOGY. Accurate, in-depth information for understanding and assessing targeted markets

Zhao Y Y et al. Ann Intern Med 2012;156:

The Cost of Overweight and Obesity on the Island of Ireland

Lumify. Lumify reimbursement guide {D DOCX / 1

Case study #1: OHDSI in Europe. Christian Reich QuintilesIMS

REFERENCE CODE GDHC282DFR PUBLICATION DATE OCTOBER 2013 BELVIQ (OBESITY) - FORECAST AND MARKET ANALYSIS TO 2022

Outcome Statement: National Stakeholders Meeting on Quality Use of Medicines to Optimise Ageing in Older Australians

How does Active Mobility. Dr. Ute Winkler, Federal Ministry of Health, Germany

How EHRA/ESC ventures into Horizon2020 funded trials. Nikos Dagres Chair of EHRA Scientific Initiatives Committee

RE: CMS-4130-P (Medicare Program; Policy and Technical Changes to the Medicare Prescription Drug Benefit)

Transcription:

03. March 2017 INSIGHTS INTO ADHD CARE IN GERMANY BASED ON SHI CLAIMS DATA Results of the CoCA Study (Horizon 2020)

Who are we? HGC looks back on close to 30 years of experience in the health care sector Our company Founded in 1989, acquired by the Vendus Group in 2011 Based in Düsseldorf and Berlin Consulting and specialized service offerings for Industry (pharmaceutical producers, medical technology) Service Providers (Hospitals, Medical Service Centers, Physician Networks, Care Facilities, Social Service Providers) Public Sector (State and Federal Ministries, Industry Associations, Municipal Authorities) Cross-disciplinary team from: Health Insurance Sector University-Run Clinics Health Economics / Research Market Access and HEOR Pharmaceutical and med-tech industries (Marketing, Operations, Medical Affairs) Industry Our core skills Market Access, HEOR, and integrated medical care concepts (from health-economics models value dossiers) Patient Journey in the real world for Market Access, Marketing, and Operations Innovative Commercial Models (Digital, Telemarketing and Field Management) Late-Phase Brand Optimization Healthcare Service Providers Market and Competitive Analyses, Service Portfolio Comprehensive Regional Supply Management Predictive Schedule Management Referral and Accessibility Management Public Sector Demographics and Morbidity Forecasts Municipal Healthcare Supply Solutions ( E-Doctor ) Horizon 2020 research projects Page 2

HGC is part of the Horizon 2020 CoCA Study (# 667302) 17 partners from 8 European countries and the US are involved in the CoCA study Our work package (WP1) Research: Epidemiology and Socioeconomic impact Descriptive analyses of SHI claims data to display the direct costs and the comorbidity clusters of SUD, obesity, anxiety/mood disorders for patients with ADHD in Germany provided by the public sick fund compared to a reference group created 1:1 without an ADHD-diagnosis and adjusted by age and sex. Cost-of-illness model (COI) to model the long-term, lifetime direct and indirect costs for patients with ADHD CoCA: Comorbid Conditions of Attention Deficit / Hyperactivity Disorder Source: http://www.ru.nl/donders/agenda-news/vm-news/6-mio-euro-coca-research-adhd/ Page 3 SHI= statutory health insurance

Which know-how did we contribute to the CoCA Study? We analyzed semi-exclusive SHI* claims data regarding ADHD comorbidities and therapy management and built a COI model Seite 4 Page 4 4 million patients** 5.5% representative sample of Germany cross sectional & longitudinal SHI claims data comprise Demography age sex region Outpatient sector EBM ICD Inpatient sector DRG OPS ICD Drug prescription ATC PZN Medical aids and remedies Sickness leave days *SHI= statutory health insurance **adjusted; 24 millions patients about 6 years

Results of the CoCA study - Overview Results of SHI claims data analyses show increasing ADHD patient numbers and cost differences compared to reference group Cohort characteristics Patient characteristics Relative increase of number of diagnosed ADHD patients 2009-2014 +47% Ratio male: female across all age groups (2014) Female n= 6586 Male n=18714 26% male 74% female Average age of ADHD patient (2014) 14,7 years 17,7 years SD:8,8 Median:13 SD:12,9 Median:13 Comorbidities Young ADHD patients suffer mainly from development disorders, while older patients suffer more often from depression compared to the reference group Prevalence in Germany in 2014 over all age groups extrapolated from database 0,67%* Biggest difference in total costs (2014) per ADHD patient compared to the reference group + 2360 p.a. Costs Cost difference per multimorbid* patient with ADHD and reference group (2014) + 1688 p.a. Cost difference for comorbidities per ADHD patient vs. reference (2014) SUD + 2670 p.a. Obesity Mood + 1754 p.a. + 1436 p.a. (in age group 31-50) (across all age groups) Anxiety + 1689 p.a. Page 5 * Multimorbidity is defined through the occurrence of at least 2 of the defined comorbidities (SUD, Obesity, Mood Disorder, Anxiety Disorder)

SHI data-based integrated care programmes could be a topic for further studies in the future Based on our work we already identified a gap in ADHD care for patients, aged 18 to 30 years a starting point for care improvement Including criteria Inpatient sector Outpatient sector 1 Incident patients First contact GP 2 Transition Q1 Q2 Q3 Q4 Pediatrician E- Health To close this gap and improve care, we are currently developing a concept building upon a specialized multimodal pathway aiming at funding through Innovation Fonds Page 6

Do you want to learn more about HGC? Our expertise and services aim at supporting --- Decision makers in the healthcare sector and public health system Scientific Working Groups who seek health-economic support for Research Projects Stakeholders who seek expert analytics the health care market Manufacturers who seek support in market access and health economic modelling Please contact Melanie May Head of Payer Affairs & Managed Care HGC GesundheitsConsult GmbH Mörsenbroicher Weg 200 40470 Düsseldorf mobile: +49 162 107 35 49 melanie.may@hgc-team.de www.gesundheitsconsult.de Page 7